Jonathan Goldman, MD
Hematology & Oncology · Santa Monica, CANPI 1750593844
Payments from drug & device makers
Across 1,313 payments — averaging $27,223 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$20M
- Pfizer$3.1M
- AstraZeneca$2.7M
- Amgen$2M
- Array Biopharma Inc$2M
- Astellas Pharma Inc$1.4M
- plus $4.6M from 23 others
Across 29 payments — averaging $1427.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$25K
- AbbVie$12K
- Bristol Myers Squibb$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 63 | $20,032,023 |
| Pfizer | 124 | $3,055,187 |
| AstraZeneca | 74 | $2,702,682 |
| Amgen | 52 | $2,002,689 |
| Array Biopharma Inc | 77 | $1,987,076 |
| Astellas Pharma Inc | 480 | $1,384,610 |
| AbbVie | 171 | $1,303,722 |
| Janssen Research & Development, LLC | 71 | $908,646 |
| Puma Biotechnology, Inc. | 31 | $705,583 |
| Eli Lilly | 23 | $616,613 |
| Genentech, Inc. | 34 | $283,851 |
| E.r. Squibb & Sons, L.L.C. | 17 | $269,616 |
| Merck | 24 | $191,595 |
| Tesaro, Inc. | 2 | $114,995 |
| Clovis Oncology, Inc. | 1 | $87,757 |
| Astrazeneca UK Limited | 22 | $26,083 |
| Spectrum Pharmaceuticals Inc. | 5 | $19,477 |
| Genentech USA, Inc. | 9 | $9,793 |
| Astrazeneca AB | 5 | $9,005 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $7,614 |
| Daiichi Sankyo Inc. | 1 | $7,203 |
| Sanofi US Services Inc. | 1 | $5,481 |
| Gilead | 5 | $4,055 |
| Jazz Pharmaceuticals Inc. | 2 | $3,340 |
| Novartis | 6 | $2,547 |
| Sanofi | 3 | $1,317 |
| Janssen Scientific Affairs, LLC | 2 | $1,041 |
| Johnson & Johnson | 1 | $318 |
| Serpex Medical Inc | 1 | $225 |
How this compares
$35,744,140 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Santa Monica
- Omid HamidSanta Monica$23.7M
- Aditya BardiaSanta Monica$22.1M
- Zev WainbergSanta Monica$19.3M
- Richard FinnSanta Monica$9.9M
- Aaron LisbergSanta Monica$9.6M
- Steven OdaySanta Monica$3.7M
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Nicholas McAndrewLos Angeles$22.9M
- Joseph TuscanoSacramento$20.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.